Ubs Group Ag Cytom X Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 69,135 shares of CTMX stock, worth $69,135. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,135

Previous 70,368 1.75%

Holding current value

$69,135

Previous $85,000 4.71%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.51 $1,380 - $1,861	-1,233 Reduced 1.75%	69,135 $81,000
Q2 2024 Aug 13, 2024	BUY	$1.21 - $5.13 $60,348 - $255,858	49,875 Added 243.38%	70,368 $85,000
Q1 2024 May 13, 2024	BUY	$1.41 - $2.74 $628 - $1,222	446 Added 2.22%	20,493 $44,000
Q4 2023 Feb 09, 2024	BUY	$1.07 - $1.55 $1,438 - $2,083	1,344 Added 7.19%	20,047 $31,000
Q3 2023 Nov 09, 2023	SELL	$1.26 - $1.87 $3,448 - $5,118	-2,737 Reduced 12.77%	18,703 $24,000
Q2 2023 Aug 11, 2023	SELL	$1.41 - $1.92 $7,547 - $10,277	-5,353 Reduced 19.98%	21,440 $36,000
Q1 2023 May 12, 2023	SELL	$1.48 - $2.88 $28,130 - $54,740	-19,007 Reduced 41.5%	26,793 $40,000
Q4 2022 Feb 08, 2023	BUY	$1.19 - $1.91 $33,328 - $53,493	28,007 Added 157.4%	45,800 $73,000
Q3 2022 Nov 10, 2022	BUY	$1.23 - $1.97 $16,709 - $26,762	13,585 Added 322.84%	17,793 $26,000
Q2 2022 Aug 10, 2022	BUY	$1.53 - $2.89 $3,825 - $7,225	2,500 Added 146.37%	4,208 $8,000
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $370,523 - $649,457	-138,773 Reduced 98.78%	1,708 $5,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $64,598 - $123,353	-16,692 Reduced 10.62%	140,481 $608,000
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $569,903 - $848,258	131,922 Added 522.44%	157,173 $800,000
Q2 2021 Aug 13, 2021	SELL	$6.33 - $9.91 $355,802 - $557,031	-56,209 Reduced 69.0%	25,251 $160,000
Q1 2021 May 12, 2021	BUY	$6.6 - $9.0 $528,343 - $720,468	80,052 Added 5685.51%	81,460 $630,000
Q4 2020 Feb 11, 2021	BUY	$6.47 - $7.9 $1,345 - $1,643	208 Added 17.33%	1,408 $9,000
Q2 2020 Jul 31, 2020	SELL	$7.4 - $14.64 $158,781 - $314,130	-21,457 Reduced 94.7%	1,200 $10,000
Q1 2020 May 01, 2020	SELL	$3.61 - $8.6 $124,696 - $297,061	-34,542 Reduced 60.39%	22,657 $174,000
Q4 2019 Feb 14, 2020	SELL	$5.17 - $8.91 $165,605 - $285,405	-32,032 Reduced 35.9%	57,199 $475,000
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $482,674 - $801,186	65,403 Added 274.48%	89,231 $658,000
Q2 2019 Aug 14, 2019	BUY	$9.35 - $11.41 $110,236 - $134,523	11,790 Added 97.94%	23,828 $267,000
Q1 2019 May 14, 2019	SELL	$9.5 - $19.16 $713,193 - $1.44 Million	-75,073 Reduced 86.18%	12,038 $130,000
Q4 2018 Feb 14, 2019	BUY	$12.69 - $18.61 $955,024 - $1.4 Million	75,258 Added 634.93%	87,111 $1.32 Million
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $172,173 - $252,057	9,544 Added 413.34%	11,853 $219,000
Q2 2018 Aug 14, 2018	SELL	$21.38 - $29.68 $932,766 - $1.29 Million	-43,628 Reduced 94.97%	2,309 $53,000
Q1 2018 May 15, 2018	BUY	$21.76 - $34.22 $756,529 - $1.19 Million	34,767 Added 311.25%	45,937 $1.31 Million
Q4 2017 Feb 14, 2018	SELL	$19.0 - $23.09 $78,831 - $95,800	-4,149 Reduced 27.08%	11,170 $236,000
Q3 2017 Nov 14, 2017	BUY	$13.53 - $18.17 $173,184 - $232,576	12,800 Added 508.14%	15,319 $278,000
Q2 2017 Aug 14, 2017	SELL	N/A	-525 Reduced 17.25%	2,519 $39,000
Q1 2017 Nov 14, 2017	BUY	N/A	3,044	3,044 $53,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.4M

Call Options Held

112K

Put Options Held

8.3K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account